HRMY or ARGX: Which Is the Better Value Stock Right Now?Zacks Investment Research · 2 days ago
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?Zacks Investment Research · 2 days ago
Revisiting Former Stock Picks Marriott, Logitech, Harmony BiosciencesBarrons · 2 days ago
Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over ItSeeking Alpha · 3 days ago
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewsWire · 4 days ago
Harmony Biosciences (NASDAQ:HRMY) Earns “Buy” Rating from Needham & Company LLCDefense World · 5 days agoHarmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | $0.96 | $1.28 | Beat |
| May 7, 2026 | $0.76 | $0.55 | Miss |
| Feb 24, 2026 | $0.84 | $0.38 | Miss |
| Nov 4, 2025 | $0.92 | $0.87 | Miss |
| Aug 5, 2025 | $0.78 | $0.68 | Miss |
| May 6, 2025 | $0.59 | $0.78 | Beat |